Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02420015 · ClinicalTrials.gov registry record · Phase 4
Mobile Health Technology to Enhance Abstinence in Smokers With Schizophrenia
A Phase 4 study, sponsored by Duke University.
- Completed
- Registry status
- Phase 4
- Development phase
- 35
- Enrollment target
NCT02420015: Completed Phase 4 study, sponsored by Duke University.
NCT02420015 is a Phase 4 study that has completed, run by Duke University. The registered enrollment target is 35 participants, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (93% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02420015, a Phase 4 study, has completed, sponsored by Duke University.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 35 participants
- Enrollment target
Study Summary
This study is designed to evaluate if a treatment the investigators call iCOMMIT is effective at helping smokers with schizophrenia stop smoking. iCOMMIT is a smoking cessation treatment that combines mobile technology with behavioral strategies, counseling, and medications.
Primary Outcome
Prolonged abstinence will exclude tobacco use in the first two weeks following the quit date, as is consistent with other smoking cessation trials.
Interventions
- DRUG Bupropion
- DRUG Nicotine replacement therapy
- BEHAVIORAL Mobile Contingency Management
- BEHAVIORAL cognitive-behavioral smoking cessation counseling
- BEHAVIORAL Stay Quit Coach
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 35 participants |
| Start Date | 2017-03-27 |
| Est. Completion | 2019-01-24 |
| Phase | Phase 4 |
What the finished NCT02420015 record still lists
NCT02420015 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 35 participants, a relatively small participant target, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (93% lower).
The record links to 0 conditions, and to 5 interventions - of which Bupropion is the first listed.
NCT02420015 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02420015 about?
NCT02420015 is a clinical study titled "Mobile Health Technology to Enhance Abstinence in Smokers With Schizophrenia". This study is designed to evaluate if a treatment the investigators call iCOMMIT is effective at helping smokers with schizophrenia stop smoking. iCOMMIT is a smoking cessation treatment that combines mobile technology with behavioral strategies, counseling, and medications.
What is the current status of trial NCT02420015?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 35 participants. The study started on 2017-03-27. Estimated completion is 2019-01-24.
What interventions are being tested in trial NCT02420015?
The interventions under investigation include: Bupropion (DRUG), Nicotine replacement therapy (DRUG), Mobile Contingency Management (BEHAVIORAL), cognitive-behavioral smoking cessation counseling (BEHAVIORAL), Stay Quit Coach (BEHAVIORAL).
Who is sponsoring clinical trial NCT02420015?
This trial is sponsored by Duke University, which has 1,725 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02420015's enrollment target sits among peer trials
35 1506th of 2000 higher than 481 of 2,000 other Phase 4 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 4 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01697371 · 35 participants · NA
Proton Therapy in the Treatment of Liver Metastases
- NCT01940757 · 35 participants · Phase 1
Experimental Infection of Hookworm-naïve Adults With Dermally-applied Infectious Necator Americanus Hookworm Larvae
- NCT02235857 · 35 participants · NA
Post Approval Study of Liposorber LA-15 System for the Treatment of Focal Segmental Glomerulosclerosis in Children
- NCT02637934 · 35 participants · Phase 1
Phase I Pilot Study of Biodistribution, Metabolism and Excretion of Novel Radiotracer [18F]Fluorthanatrace (FTT) by PET/CT
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI